Successful Treatment with Emicizumab of Patient with Type 2N Normandy and Severe Hemophilia a

被引：0
|
作者：
Bryant, Paulette [1 ]
Lineberger, Elizabeth [2 ]
Carr, Courtney Huckel [2 ]
Kaus, Angela [2 ]
机构：
[1] Presbyterian Blume Pediat Hem & Onc, Charlotte, NC USA
[2] St Jude Affiliate Clin Hemby Childrens Hosp, Charlotte, NC USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-153096
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4249
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Additional use of Factor VIII to a Patient with Severe Hemophilia a Receiving Emicizumab Prophylaxis from Infancy
    Yagi, Takeshi
    Matsuda, Takehiro
    Inamine, Itsuki
    Higa, Takeshi
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [32] Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays
    Kizilocak, Hande
    Yukhtman, Clara Lana
    Marquez-Casas, Elizabeth
    Lee, Jeanie
    Donkin, Jennifer
    Young, Guy
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10 : 1 - 9
  • [33] Successful endoscopic sphincterotomy for choledocholithiasis in a patient with severe hemophilia A and inhibitors
    Sugiura R.
    Kuwatani M.
    Kawakubo K.
    Sano I.
    Kato S.
    Endo T.
    Sakamoto N.
    Clinical Journal of Gastroenterology, 2018, 11 (3) : 188 - 192
  • [34] Successful double bypass in a patient with severe hemophilia A: a case report
    Barillari, Giovanni
    Pasca, Samantha
    Erice, Filippo
    Livi, Ugolino
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2012, 33 (02) : 193 - 196
  • [35] PERI-OPERATIVE ORTHOPEDIC MANAGEMENT OF A PATIENT WITH SEVERE HEMOPHILIA A AND A FACTOR VIII INHIBITOR ON EMICIZUMAB
    Rupani, Natasha S.
    Khalife, Roy
    Tinmouth, Alan
    Ward, Sarah
    Sholzberg, Michelle
    Teitel, Jerry
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E93 - E93
  • [36] Central Line-Associated Thrombus Formation in an Inhibitor Negative Severe Hemophilia A Patient on Emicizumab
    George, Nicholas B.
    Paschke, Alexander
    Scott, Katie
    BLOOD, 2019, 134
  • [37] EMICIZUMAB TREATMENT IN PATIENT WITH ACQUIRED HEMOPHILIA CAN BE A RELAY TO BYPASSING AGENTS: A CASE REPORT
    Toutain, I. Martin
    Launois, A.
    Lambert, J.
    Longval, T.
    Merabet, F.
    Jaidi, R.
    LeDore, S.
    Ferre, E.
    De Raucourt, E.
    Flaujac, C.
    HAEMOPHILIA, 2023, 29 : 98 - 98
  • [38] BIOLOGICAL EFFECT OF DESMOPRESSIN IN 8 PATIENTS WITH TYPE 2N (NORMANDY) VON-WILLEBRAND-DISEASE
    MAZURIER, C
    GAUCHER, C
    JORIEUX, S
    GOUDEMAND, M
    DURIN, A
    GOUAULTHEILMANN, M
    GOUDEMAND, J
    HANSS, M
    PARQUETGERNEZ, A
    PERNOD, G
    SULTAN, Y
    BRITISH JOURNAL OF HAEMATOLOGY, 1994, 88 (04) : 849 - 854
  • [39] Assessment of the impact of pharmaceutical consultations at initiation of a treatment with emicizumab in patients with severe hemophilia A without inhibitors
    Allah, M. Nasr
    Pieragostini, R.
    Oka, G.
    Batista, R.
    Stieltjes, N.
    Lopez, I.
    ANNALES PHARMACEUTIQUES FRANCAISES, 2022, 80 (06): : 915 - 922
  • [40] Osteoporosis and osteopenia in patient with severe and moderate type hemophilia A
    Chen, Y. C.
    Cheng, S-N
    Pan, R-Y
    Li, T. Y.
    Hu, S. H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 800 - 800
12345